Compare Duke Energy Corp (DUK) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Novartis AG — how do they compare? Duke Energy Corp trades at $116.51 (market cap $90.06B), while Novartis AG trades at $142.74 (market cap $274.00B). The key difference: Novartis AG is far larger — about 3× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.76%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Novartis AG for 82 Days on average.
| DUK | NVS | |
|---|---|---|
Market Cap | $90.06B | $274.00B |
Volume | 3,988,081 | 1,852,137 |
Sector | Utilities | Health |
52-Week High | $133.46 | $168.62 |
52-Week Low | $113.23 | $121.80 |
Typical Hold Time | 74 Days | 82 Days |
Enterprise Value | $182.56B | $315.32B |
Dividend Yield | 3.76% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.02% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 15.78% net income margin. Recent news highlights dividend stability and data center growth opportunities, though rising Treasury yields pressure utility stocks. The company maintains solid cash flow from operations of $12.33B in 2025, supporting its dividend payments.
DUK offers a balanced outlook with a consensus price target of $135.33, implying upside, but faces risks from high debt levels and interest rate sensitivity. Earnings growth and data center demand are key catalysts, while investor sentiment is mixed amid macroeconomic headwinds.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
